A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT

Trial Profile

A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Prostate cancer vaccine (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Onyvax
  • Most Recent Events

    • 22 Jun 2011 New source identified and integrated (European Clinical Trials Database record EudraCT2006-001619-31).
    • 17 Mar 2008 The primary endpont is expected to be reached in the first half of 2009, as reported in an Onyvax media release.
    • 08 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top